

1 **Microsatellites reveal high polymorphism and high potential for use in**
2 **antimalarial efficacy studies in areas with different transmission**
3 **intensities in mainland Tanzania**

4

5 Deus S. Ishengoma^{1, 2, 3*}, Celine I. Mandara¹, Rashid A. Madebe¹, Marian
6 Warsame⁴, Billy Ngasala^{5,6}, Abdunoor M. Kabanywany⁷, Muhidin K.
7 Mahende^{7,8}, Erasmus Kamugisha⁸, Reginald A. Kavishe⁹, Florida Muro⁹,
8 Renata Mandike¹⁰, Sigsbert Mkude¹⁰, Frank Chacky¹⁰, Ritha Njau¹¹, Troy
9 Martin¹², Ally Mohamed¹⁰, Jeffrey A. Bailey¹³, Abebe A. Fola¹³

10

11 ¹*National Institute for Medical Research, Dar es Salaam, Tanzania*

12 ²*Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia*

13 ³*Harvard T. H Chan School of Public Health, Harvard University, Boston, MA,*
14 *USA*

15 ⁴*Gothenburg University, Gothenburg, Sweden.*

16 ⁵*Department of Parasitology, School of Public Health, Muhimbili University of*
17 *Health and Allied Sciences, Dar es Salaam, Tanzania*

18 ⁶*Department of Women's and Children's Health, International Maternal and*
19 *Child Health (IMCH), Uppsala University, Uppsala, Sweden*

20 ⁷*Ifakara Health Institute, Dar es Salaam, Tanzania*

21 ⁸*Catholic University of Health and Allied Sciences/Bugando Medical Centre,*
22 *Mwanza, Tanzania*

23 ⁹*Kilimanjaro Christian Medical University College/Kilimanjaro Christian*
24 *Medical Centre, Moshi, Tanzania*

25 ¹⁰*National Malaria Control Programme, Ministry of Health, Dodoma, Tanzania*

26 ¹¹*Malariologist and Public Health Specialist, Dar es Salaam, Tanzania*

27 ¹²*HIV Vaccine Trials Network, Fred Hutch Cancer Research Centre, Seattle,*
28 *Washington, USA*

29 ¹³*Department of Pathology and Laboratory Medicine, Warren Alpert Medical*
30 *School, Brown University, Providence, RI, USA.*

31

32

33 *Corresponding author

34 Email: deusishe@yahoo.com

35

36

37

38 **Abstract**

39 **Background**

40 Tanzania is currently implementing therapeutic efficacy studies (TES) in areas
41 of varying malaria transmission intensities as per the World Health
42 Organization's (WHO) recommendations. In TES, distinguishing reinfection
43 from recrudescence is critical for the determination of antimalarial efficacy.
44 Recently, the WHO recommended genotyping polymorphic coding genes
45 (*msp1*, *msp2*, and *glurp*) and highly polymorphic neutral microsatellites in
46 *Plasmodium falciparum* to adjust the efficacy of antimalarials in TES. This study
47 assessed the polymorphisms of six neutral microsatellite markers and their
48 potential use in TES, which are routinely performed in Tanzania.

49 **Methods**

50 *P. falciparum* samples were obtained from four TES sentinel sites, Kibaha
51 (Pwani), Mkuzi (Tanga), Mlimba (Morogoro), and Ujiji (Kigoma), between April
52 and September 2016. Parasite genomic DNA was extracted from dried blood
53 spots on filter papers using commercial kits. Genotyping was performed using
54 six microsatellites (Poly- α , P α PK2, TA1, C3M69, C2M34 and 2490) by the
55 capillary method, and the data were analyzed to determine the extent of
56 polymorphisms and genetic diversity at the four sites.

57 **Results**

58 Overall, 83 (88.3%) of the 94 samples were successfully genotyped (with
59 positive results for $\geq 50.0\%$ of the markers), and $>50.0\%$ (range = 47.6-59.1%)
60 were polyclonal, with the mean multiplicity of infection ranging from 1.68 to 1.88
61 among the four sites. There was high genetic diversity but limited variability
62 among the four sites based on mean allelic richness ($R_s = 7.48$, range= 7.27-
63 8.03, for an adjusted minimum sample size of 18 per site) and mean expected
64 heterozygosity ($H_e = 0.83$, range= 0.80-0.85). Cluster analysis of haplotypes
65 using STRUCTURE, principal component analysis, and pairwise genetic
66 differentiation (F_{ST}) did not detect any population structure, and isolates
67 clustered independently of geographic origin. Of the six markers, Poly- α was
68 the most polymorphic, followed by C2M34, TA1 and C3M69, while 2490 was
69 the least polymorphic.

70 **Conclusion**

71 Microsatellite genotyping revealed high polyclonality and genetic diversity but
72 without any significant population structure. Poly- α , C2M34 and TA1 were the
73 top polymorphic markers and could be adopted for use in TES in Tanzania.

74

75 *Key words: Plasmodium falciparum, falciparum malaria, therapeutic efficacy*
76 *studies, microsatellites, Tanzania.*

77

78 **Background**

79 Malaria case management is one of the main interventions for malaria control,
80 and together with vector control tools have significantly contributed to the
81 reduction in morbidity and mortality that was reported between 2000 and 2015
82 [1]. However, this strategy has been compromised by antimalaria drug
83 resistance which led to the withdrawal of chloroquine and SP and replacing
84 them with artemisinin combination therapy (ACT) [2]. In 2006, Tanzania
85 introduced ACTs with artemether-lumefantrine (AL) for the treatment of
86 uncomplicated malaria, and the drug was officially rolled out in January 2007
87 [3]. AL, which is a fixed-dose combination of artemether and lumefantrine, has
88 been effectively used for the past 16 years for the treatment of malaria [4], and
89 studies undertaken in Tanzania have shown that it has maintained high and
90 optimal efficacy and safety with high cure rates and minimal safety concerns
91 [5–9]. Previous reports showed that ART-R emerged in the Mekong Subregion
92 of Southeast Asia following deployment of ACTs and was associated with
93 delayed parasite clearance [10,11], extended survival of ring stage [12,13] and
94 mutations in the kelch13 (*k-13*) gene [14–16]. Until 2018, mutations associated
95 with artemisinin resistance had not been reported in Africa [4], and ACTs
96 retained high cure rates for the treatment of uncomplicated falciparum malaria
97 [4]. However, recent studies confirmed artemisinin partial resistance in Rwanda
98 with mutations at codon R561H (>5%) of the *k-13* gene and day 3 positivity
99 rates (>10%), but AL still had sufficient cure rates (>90%) [17,18]. Similarly,
100 artemisinin partial resistance has been reported in Uganda with mutations in
101 the *k-13* gene at codons A675V and C469Y [19], Tanzania with 561H mutations
102 (Ishengoma D. Unpublished data) and in Eritrea for mutations at codon R622I
103 [20]. For lumefantrine, studies conducted in Tanzania [9] and elsewhere have
104 reported an increase in polymorphisms in the multidrug resistance 1 gene
105 (*mdr1*), which are associated with reduced susceptibility to lumefantrine [21].
106 The impacts of the polymorphism in the *mdr1* gene on the performance of AL
107 are not clearly known, and thus, sustained surveillance is needed to monitor
108 the performance of this important ACT and allow early detection of any
109 emergence of resistance before its efficacy is compromised.

110

111 In Tanzania, the National Malaria Control Programme (NMCP) and its partners
112 have been collaboratively implementing therapeutic efficacy studies (TES)
113 since 1997 [22,23]. These TES are based on the WHO standard protocol
114 [24,25] and aim at monitoring the efficacy and safety of antimalarials used for
115 the treatment of uncomplicated malaria in children aged six months to 10 years.
116 For Tanzania, studies have focused on first-line antimalarial (artemether-
117 lumefantrine – AL) and alternative artemisinin-based combination therapies
118 (ACTs). The current alternative ACTs covered in TES include artesunate-
119 amodiaquine (ASAQ), which is the first-line drug in Zanzibar [26], and
120 dihydroartemisinin-piperaquine, which was included in the National Guidelines
121 for Diagnosis and Treatment of Malaria from 2014 [22,27]


122

123 According to the WHO protocol [24,28,29], TES has two components: field data
124 and sample collection and laboratory analyses. The laboratory analyses aim at
125 distinguishing recrudescence from new infections in patients with recurrent
126 infections and generating data of molecular markers in the genes associated
127 with resistance or reduced sensitivity/susceptibility of the parasites to the drugs.
128 To distinguish recrudescence from new infection, the old WHO protocol, which
129 was developed in 2008, recommended genotyping of three polymorphic genes,
130 including merozoite surface protein 1 and 2 (*mSP1 and mSP2*) and glutamate-
131 rich protein (*glurp*) [29]. Recently, the WHO has recommended a new protocol
132 that recommends genotyping both *mSP1* and *mSP2* and one or two highly
133 polymorphic microsatellite markers [30]. Several microsatellite markers have
134 been utilized in studies of malaria parasites, but they differ in their level of
135 polymorphisms and informativeness [13,31]. Of the different microsatellites,
136 WHO recommends using poly-A and any of the other two markers, TAE1 and
137 Pfk2. However, these markers have not been optimized in different countries to
138 determine if they are indeed sufficiently polymorphic and sensitive and can
139 reliably be used for genotyping within TES. This study was therefore
140 undertaken to assess the polymorphisms of six microsatellite markers (Poly-A,
141 Pfk2, TA1, C3M69, C2M34 and 2490) for potential use in TES in Tanzania.
142 The findings provide important information on these markers and parasite
143 populations in the country and will facilitate future genomic studies and their
144 application in TES and malaria surveillance as well.

145 **Materials and Methods**

146 **Study sites**

147 The samples used for this study were obtained from clinical malaria cases
148 sampled in a TES that was conducted during and after the long rainy season
149 between April and September 2016 [9]. It was undertaken in four geographically
150 and epidemiologically distinct areas of Tanzania (Kibaha – Pwani, Mkuzi –
151 Tanga, Mlimba – Morogoro and Ujiji - Kigoma), and these sites have been
152 NMCP sentinel sites for monitoring of antimalarial efficacy since 1997 (Figure
153 1) [22,23]. The study sites were selected to represent distinct geographic areas
154 of Tanzania. In Kibaha district of the coastal region (Pwani), the study was
155 conducted at Yombo Dispensary, which is located in an area that has
156 transitioned from high to low malaria transmission (with prevalence by mRDTs
157 in under-fives of <10% in 2017)[32–34]. In Tanga region, the study site was
158 Mkuzi health center, which is located in Muheza district. Areas around Mkuzi
159 have reported a progressive decline in malaria prevalence (in individuals aged
160 < 20 years) from over 80% in the 1990s to <10% in 2017 [35,36]. The Ujiji health
161 center is located in Kigoma urban district of the Kigoma region. Parasite
162 prevalence among under-fives (by mRDTs) in Kigoma increased from 19.6% in
163 2007 to 38.1% in 2016, followed by a decline to 24.4% in 2017, but this was the
164 highest prevalence in the country [32–34]. The fourth site of Mlimba health
165 center (parasite prevalence among under-fives in 2017 was <10%) is located in
166 Kilombero district of Morogoro region and has experienced a significant decline
167 in malaria burden in the last two decades [37]. Additional details of the study
168 sites were given elsewhere [9,38].



169

170 **Figure 1.** Map of Tanzania showing the four study sites of Kibaha, Mkuzi,
171 Mlimba, and Ujiji. (Parasite prevalence data were obtained from the School
172 Malaria Parasitological Survey of 2015[39].

173

174 **Study design and target population**

175 Samples used for this analysis were collected during a single-arm prospective
176 *in vivo* TES that assessed the therapeutic efficacy and safety of artemether-
177 lumefantrine (AL) for the treatment of uncomplicated falciparum malaria and
178 markers of artemisinin and lumefantrine resistance [9]. The study recruited 344
179 out of the 963 febrile children aged 6 months to 10 years who were screened
180 according to the WHO protocol [24,25].

181

182 **Sample collection**

183 Enrolled children were treated with AL and followed up for 28 days with clinical
184 and parasitological assessments in the first three days post-treatment (day 1,
185 2 and 3) and once weekly from day 7 to 28 [9]. Thick and thin films were taken
186 for the detection of malaria parasites during each visit. Dried blood spots (DBS)
187 on filter papers were also collected at enrollment and from day 7 onward for
188 molecular analyses of malaria parasites.

189 **Sample processing and genotyping**

190 Parasite genomic DNA was extracted from DBS using QIAamp DNA mini-kits
191 (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions.
192 Analysis of six neutral microsatellite markers was undertaken at the Centers for
193 Disease Control and Prevention's (CDC) Malaria Laboratory in Atlanta, USA. A
194 total of 94 samples were collected on day zero among patients with recurrent
195 infections and a random selection of other samples from patients without
196 recurrent infections collected on day zero were selected for microsatellite
197 genotyping. These samples were analyzed to distinguish recrudescence from
198 new infections as previously reported [9] and to determine genetic diversity in
199 the study populations. The microsatellite markers (TA1 on chromosome 6, Poly
200 – α on chromosome 4, PfPK2 on chromosome 12, 2490 on chromosome 10,
201 C2M34-313 on chromosome 2 and C2M69-383 on chromosome 3) were
202 genotyped by nested PCR for all except C2M34-313 and C2M69-383 (which
203 were analyzed with a single step PCR). Fragment size was measured by
204 capillary electrophoresis on ABI 3033 (Applied Biosystems) and scored using
205 GeneMapper® Software Version 4.0 (Applied Biosystems) [40,41].

206

207 **Ethical considerations**

208 Ethical clearance was obtained from the medical research coordinating
209 committee (MRCC) of the National Institute for Medical Research (NIMR), while
210 permission to conduct the study at the health facilities was sought in writing
211 from the relevant regional and district medical authorities. Ethical clearance
212 from the CDC was not needed because the assessments performed at the CDC
213 Malaria Laboratory, using samples without linked identifiers (deidentified
214 samples), were determined by the CDC Center of Global Health's Human
215 Research Protection Coordinator to not constitute an engagement in human
216 subjects' research. Informed consent (oral and written) was obtained from
217 parents or guardians before patients were screened to assess their eligibility
218 for possible inclusion in the study.

219

220

221

222

223 **Data analysis**

224 ***Population genetic analysis***

225 GeneScan chromatograms were analyzed using GeneMapper® Software
226 Version 4.0 (Applied Biosystems) with an internal size standard of 350 Rox.
227 The stutter window was set to 2.5 for 2 bp repeats, 3.5 for 3 bp repeats and 4.5
228 for 4 bp repeats. The stutter ratio was set to 0.4 for the four markers, and for
229 the remaining two markers (C2M34 and C3M69), a relatively higher stutter ratio
230 (0.6) was set, as they showed greater stuttering during manual inspection of
231 chromatograms. A cut-off of 1,000 relative fluorescence units (RFUs) was used
232 to distinguish true peaks from background signals. All dominant peaks (i.e.,
233 those peaks within the size range with the highest RFUs) and any additional
234 alleles with a minimum 30% height of the dominant allele were scored. All
235 chromatograms were inspected manually to confirm call quality. Then, samples
236 with low RFUs were re-analysed with a minimum fluorescence of 200 RFU.
237 Microsatellite haplotypes comprising more than 3 (50%) successfully typed
238 markers were selected for further analysis.

239

240 For downstream population genetics analysis, multilocus microsatellite allele
241 data were converted into different formats using CONVERT software version
242 1.3.1. The number of genetically distinct parasite clones (multiplicity of infection,
243 MOI) was calculated considering the maximum number of alleles detected at
244 any of the six microsatellite loci. The number of clones for each population was
245 determined by summing the total number of clones per isolate. The mean MOI
246 for each population was calculated by dividing the total number of clones
247 detected by the number of samples. Genetic diversity was measured by
248 calculating allelic richness (R_s) and expected heterozygosity (H_e) using FSTAT
249 software version 2.9.3.2 [42]. As a measure of inbreeding within populations
250 (non-random association of alleles), the standardized index of association (I_A^S)
251 was used to measure multilocus linkage disequilibrium (LD) in each parasite
252 population using LIAN version 3.6, applying a Monte Carlo test with 100,000 re-
253 sampling steps [43].

254

255 STRUCTURE version 2.3.4 [44] was used to determine the number of
256 population clusters (K) and whether haplotypes clustered according to their

257 geographic origin. The analysis was run 20 times for $K = 1$ to 20, for 100,000
258 Monte Carlo Markov Chain (MCMC) iterations after a burn-in period of 100,000,
259 and using the admixture model. To obtain the optimal K value, the method of
260 Evanno *et al* [44] was used to calculate ΔK from the log probability of the data
261 ($\text{LnP}[D]$) using STRUCTURE HARVESTER [45]. The STRUCTURE bar plots
262 (ancestry coefficients) were visualized using Cluster Markov Package Across
263 K (CLUMPAK) [46]. Genetic differentiation between populations was measured
264 by calculating the F_{ST} statistic according to Nei [47]. Estimation of average
265 heterozygosity and genetic distance from a small number of individuals was
266 performed using the pairwise.neifst function available in the hierfstat R
267 package [48]. The Mantel test was performed to measure the associations
268 between genetic distance and geographical distance between catchments
269 using the Mantel function in the R adegenet package [49]. To assess haplotype
270 relatedness, the genetic distance metric (1-pairwise allele sharing (P_s)) was
271 calculated and used to generate phylogenetic trees using the bionj Ape R
272 package [50].

273

274 **Results**

275 From a total of 94 *P. falciparum* samples, 83 were successfully genotyped, and
276 all gave positive results for 3 (50%) or more microsatellite markers (Table 1).
277 Only single infections or dominant haplotypes constructed from multiple
278 infection data were included in downstream population genetic analyses. The
279 number of clones per sample ranged from 1 to 4, and a total of 38 (45.8%)
280 samples had single infections, followed by samples carrying two distinct
281 parasite clones ($n = 31$, 37.3%), three ($n = 12$, 14.45%), and only two samples
282 carried four distinct clones. Overall, at least 38% of the samples in each
283 population contained more than one parasite clone (polyclonal), and there was
284 limited variability in the mean MOI among populations (average MOI ranged
285 from 1.68 to 1.88) (Table 1).

286

287

288

289

290 **Table 1. Population genetic metrics of four Tanzanian *P. falciparum***
291 **populations**

Population	Prevalence (%)†	N	n	h	$R_s \pm SD$	$H_e \pm SD$	I_A^S	MOI	Polyclonality (%) #
Kibaha	13.8	25	21	19	8.03±2.8	0.85±0.12	0.1569**	1.76	47.6
Ujiji-Kigoma	35.6	23	22	22	7.48±2.1	0.84±0.10	0.1736**	1.88	59.09
Mkuzi-Muheza	22.6	25	22	22	7.79±2.4	0.82±0.14	0.1095**	1.68	54.5
Mlimba-Kilombero	30.2	21	18	18	7.56±2.3	0.80±0.20	0.0903*	1.72	55.5


292 *N*=total number of samples; *n*=number of samples successfully genotyped; *h*=
293 number of unique haplotypes; R_s = Allelic richness, H_e = expected
294 heterozygosity, I_A^S =standard index of association as a measure of multilocus
295 linkage disequilibrium (LD), MOI= multiplicity of infection (mean number of
296 clones per infection); Polyclonality= proportion of samples containing more than
297 one parasite clone †Prevalence of malaria in the study districts in the 2015
298 school malaria parasitological survey [10] *=*p*-value<0.01, **=*p*-value<0.001;
299 #Polyclonality (%) refers to the proportion of infections with >1 clones.

300

301 **No significant difference in mean multiplicity of infection among**
302 **populations**

303 In malaria endemic countries such as Tanzania, individuals often carry more
304 than one parasite clone that is genetically different, referred to as multiplicity of
305 infections (MOI), also known as complexity of infection (COI). MOI occurs either
306 due to repeated bites of infective mosquitoes or multiple clones in a single
307 mosquito inoculum [51] and decreases with declining transmission. Here, we
308 found a mean MOI of 1.73 across populations (range = 1- 4 parasite clones per
309 sample), and there was no statistically significant difference among the four
310 populations (Kruskal–Wallis test) (Figure 2).

311



312

313

314


315 **Figure 2. Multiplicity of infection in four Tanzanian *P. falciparum***
 316 **populations.**

317 *Box and whisker plots were generated from the number of clones determined*
 318 *for each microsatellite marker per population using R software. Dots indicate a*
 319 *haplotype, boxes indicate the interquartile range, the line indicates the median*
 320 *and the whiskers show the 95% confidence intervals. The numbers above the*
 321 *box plot indicate pairwise comparative p values between populations showing*
 322 *a lack of significant difference in MOI among the four sites.*

323

324

325 The association between polyclonality (proportion of multiple infections) and
 326 parasite prevalence was assessed, and a positive correlation between
 327 polyclonality and malaria prevalence was observed (based on 2015 school
 328 survey data) per population ($R = 0.97$, $p\text{-value} = 0.035$, Spearman Rank
 329 Correlation) (Figure 3). Polyclonality was lower in Kibaha and Muheza, which
 330 had a lower prevalence compared to Ujiji, with higher polyclonality and a higher
 331 prevalence of malaria.




332 **Figure 3. Association between the parasite prevalence (by mRDT) and**
333 **proportion of multiple infections (polyclonality) in four Tanzanian *P.***
334 ***falciparum* populations.** *The graph indicates a significant positive association*
335 *between polyclonal infections and parasite prevalence across different*
336 *geographic areas. Dots indicate population-level prevalence and proportion of*
337 *polyclonal infections; the blue line indicates the Spearman Rank Correlation*
338 *line, and the gray shaded region represents the 95% confidence interval.*

340

341 **High genetic diversity but significant multilocus linkage disequilibrium** 342 **(LD)**

343 Of the 83 multilocus haplotypes from successfully genotyped *P. falciparum*
344 isolates, 53 (63.8%) were complete genotypes, of which 51 (96.2%) were
345 unique and only two haplotypes were identical to each other within Kibaha
346 population. Regardless of transmission intensity, there was high genetic
347 diversity of *P. falciparum*, with limited variability among the four parasite
348 populations based on allelic richness (mean $R_S = 7.27$, range = 7.48-8.03, for
349 an adjusted minimum sample size of 18 per site) and expected heterozygosity
350 (mean $H_e = 0.83$, range = 0.80-0.85) (Table 1, Figure 4). However, according
351 to the Index of Association (I_A^S) analysis, which is a measure of multilocus
352 linkage disequilibrium (which emerges when genotypes are related), all
353 parasite populations from the four sites showed significant multilocus LD (Table
354 1). This could be explained by the presence of some degree of inbreeding
355 despite high transmission in some areas.


356



357

358

359




360

361

362 **Figure 4. Genetic diversity (Expected Heterozygosity (A), Allelic Richness**
363 **(B)) of *P. falciparum* in four geographic sites in Tanzania.**

364 *Box and Whisker plots were generated from the diversity metrics for each*
365 *microsatellite marker per population using R software. Boxes indicate the*
366 *interquartile range, the line indicates the median, and the whiskers show the*
367 *95% confidence intervals.*

368 Furthermore, the diversity of microsatellite markers was assessed, and there
369 was high variability in the alleles present per marker ($A = 3 - 13$) (Figure 5), with
370 variable frequency for the four different sites. The marker M2490 was the least
371 diverse microsatellite, with only a 3.5 mean number of distinct alleles detected
372 across the four populations, while PolyA was the most diverse microsatellite
373 marker ($A = 13$, $H_e = 0.91$), followed by C2M34 ($A = 11$, $H_e = 0.89$). These two
374 highly polymorphic markers (polyA and C2M34) and, if needed, together with
375 C3M69 and TA1 can be used for the detection of parasite clones in Tanzania.
376




377
378

379 **Figure 5. Diversity of *P. falciparum* microsatellite markers among**
380 **parasites from the four sites in Tanzania.**

381 *Box and Whisker plots were generated from unique allele counts for each*
382 *microsatellite marker using R software. Boxes indicate the interquartile range,*
383 *the line indicates the median, and the whiskers show the 95% confidence*
384 *intervals.*

385 **Lack of population structure and genetic differentiation**

386 To investigate the presence of parasite population structure among the four
387 Tanzanian sites, cluster analysis of the haplotypes was conducted using
388 STRUCTURE version 2.3.4. No evidence of any population structure from $K =$
389 $2 - 4$ was detected, and the ancestry of genotypes was equally split between
390 the genetic populations, showing no evidence of any population structure.




391

392 **Figure 6. Bayesian cluster analysis of *P. falciparum* microsatellite**
393 **haplotypes from the four sites of Tanzania.**

394 *Structure bar plots representing individual ancestry coefficients are shown for*
395 *K=2, 3 and 4, and each vertical bar represents an individual genotype and the*
396 *membership coefficient (Q) within each of the genetic populations, as defined*
397 *by the different colours.*

398

399 Further cluster analysis of haplotypes using principal component analysis
400 (PCA, with princomp function in R package) also did not detect any signature
401 of population structure and found no clustering of isolates by geographic origin
402 (Figure 7).



403

404 **Figure 7. *Plasmodium falciparum* haplotype clustering.**

405 *A) Principal component analysis (PCA) of *P. falciparum* haplotypes. Dots*
406 *indicate individual microsatellite haplotypes, and colours indicate the four*
407 *sample collection sites. B) Percentage of variance explained by each principal*
408 *component (PC).*

409 **Gene flow and population connectivity**

410 To assess gene flow and population connectivity, pairwise genetic
411 differentiation based on Jost's D metric [52] and F_{ST} according to Nei [47] were
412 calculated among the four parasite populations using the pairwise.neifst
413 function available in the hierfstat R package. Very low levels of genetic
414 differentiation were observed between populations, confirming that *P.*
415 *falciparum* populations from these sites are highly panmictic (Table 2). We also
416 conducted the Mantel test to assess the correlation between pairwise genetic
417 distance and pairwise geographic distance in km as an indication of gene flow
418 and parasite connectivity. The differentiation of parasite populations was not
419 statistically associated with geographical distance between populations and
420 therefore did not fit the Isolation-by-Distance model (Mantel statistic $r = 0.072$,
421 p -value = 0.59).

422

423 **Table 2. Pairwise genetic differentiation among parasite populations in**
424 **Tanzania**


	Kibaha	Ujiji-Kigoma	Mkuzi-Muheza	Mlimba
Kibaha		0.01	0.009	0.038
Ujiji-Kigoma	0.37		0.005	0.001
Mkuzi-Muheza	0.22	0.14		0.003
Mlimba	0.34	0.37	0.24	

Top right = pairwise F_{ST} , Left bottom = pairwise Jost's D

425

426 **Haplotype relatedness**

427 To assess relatedness in *P. falciparum*, pairwise comparisons among all
428 isolates were conducted using the dist.gene command in the R Ape package.
429 The results showed that the majority of isolates had only one identical allele
430 among all six markers on average, and only a few isolates shared more than
431 50% of the alleles (three or more alleles). Phylogenetic analysis using
432 neighbour joining trees also confirmed a lack of population structure and
433 geographic clustering of genotypes. However, there were more haplotypes
434 clustering together within populations than between populations (Figure 8).



435

436 **Figure 8 Relatedness of *P. falciparum* haplotypes in Tanzania.**

437 *Neighbour-Joining tree showing low levels of similarity of the multilocus *P.**
438 *falciparum* haplotypes between most isolates with similar haplotypes within

441

442 Discussion

443 This study included samples from four geographically distinct parasite
444 populations (located 296 to 1211 km apart) from areas with different
445 transmission intensities to assess polymorphisms of six neutral microsatellite
446 markers (Poly- α , P α PK2, TA1, C3M69, C2M34 and 2490) for potential use in
447 Tanzania. It also aimed at capturing the spatial genetic diversity and population
448 structure of Tanzanian *P. falciparum*. The findings showed that four markers
449 (Poly- α , C2M34, C3M69 and TA1) had high diversity and could be adopted as
450 validated markers for use in TES in Tanzania. As recently recommended by the
451 WHO [53] and a previous study that showed that a combination of four
452 microsatellite markers with sufficient diversity are needed in TES [54,55], these
453 microsatellite markers can be included in the revised workflow for TES in
454 Tanzania. The new panel should replace the old system based on genotyping
455 of *msp1*, *msp2* and *glurp* for distinguishing recrudescence from new infections in
456 ongoing TES in Tanzania. However, the areas around TES sites have

457 increasingly reported a decline in malaria transmission in the past two decades,
458 which suggests that continuous assessment of these and possibly other
459 microsatellite markers will be critical. This will ensure that high-resolution
460 markers are used and that the efficacy of antimalarials is not underestimated
461 due to the limited discrimination power of the markers. Additional methods such
462 as targeted amplicon sequencing can also be explored based on the capacity
463 of the laboratory, as recently recommended [56].

464

465 This study also showed high diversity and a lack of population structure and a
466 high level of polyclonality despite varying malaria prevalence among the study
467 sites. The results suggest that these areas still have high malaria transmission
468 with little evidence of a control impact on transmission dynamics. However, a
469 significant correlation between parasite prevalence and polyclonality (as a
470 proxy of malaria measure of transmission intensity) was detected as expected,
471 given that in areas with higher malaria prevalence, humans are exposed to
472 multiple mosquito bites (superinfection) or infections with multiple clones (co-
473 transmission) [57,58]. A strong correlation between parasite prevalence and
474 polyclonality has been reported in other studies [59–61] and needs to be
475 monitored as a surrogate measure of potential changes in malaria transmission
476 due to the impacts of interventions. In Papua New Guinea, *P. falciparum* MOI
477 was associated with parasite prevalence, but the diversity of the size
478 polymorphic markers remained high despite wide variation in prevalence at
479 different sites [59–61]. In contrast to these findings, a study in Indonesia [62]
480 reported lower genetic diversity, which was consistent with the low level of
481 malaria transmission at the study sites and could be a result of longer-term
482 sustained low transmission in this area compared to PNG and Tanzania.

483

484 Microsatellites are highly polymorphic, rapidly evolving and therefore may need
485 long-term sustained low transmission to detect a signal of low diversity [31]. In
486 PNG, studies have followed *P. falciparum* populations in declining transmission
487 for over nine years and reported very minor changes in microsatellite diversity
488 [63]. Moreover, high transmission intensity, high polyclonality and therefore
489 high rates of recombination between distinct clones (outcrossing) might
490 obscure the expected association between the MOI and transmission intensity

491 (prevalence) in different transmission zones. However, in low transmission
492 areas such as South America, studies conducted in Ecuador and Peru reported
493 infections containing clonal parasites with clear population structure [64,65].

494

495 In addition to the MOI as a proxy for transmission intensity, estimating the
496 extent of parasite genetic diversity and population structure is essential for a
497 deeper understanding of malaria epidemiology and transmission dynamics as
498 well as evaluating the impact of malaria control interventions [66]. Polymorphic
499 markers can also be used for the detection of different parasite clones in
500 different studies, including TES. In this study, it was shown that parasite genetic
501 diversity was high in the four Tanzanian sites regardless of the prevalence of
502 infection and that the respective parasite populations appeared to be highly
503 mixed with no clear genetic structure according to geographic origin. Thus, high
504 polymorphism at all sites and with all markers suggest that these markers
505 (especially the three topmost) can sufficiently be used in TES to distinguish
506 recrudescence from new infections, as recommended by the WHO [67].

507

508 Unlike the expectation that geographical isolation causes limited migration
509 among subpopulations and geographical population structure, there was no
510 significant genetic differentiation (measured by F_{ST}) between distant and
511 nearby parasite populations. These results suggest high malaria transmission
512 intensity and/or extensive parasite migration throughout the country despite
513 significant improvement in malaria control strategies and drastic declines in
514 malaria transmission and disease burden in recent years. These findings
515 support previous observations where genetic diversity, geographic clustering
516 and inbreeding with strong LD as population genetic signals are expected in
517 low transmission areas, whereas high proportions of polyclonal infections, high
518 diversity and panmictic parasite populations were expected in areas with high
519 levels of transmission [31]. Generally, the levels of allelic diversity, parasite
520 outcrossing, and gene flow are high in African populations, low in South
521 American populations, and intermediate in Southeast Asian populations [31].
522 The results of this study support a situation of continuing highly endemic
523 transmission dynamics in the country despite the expected substantial impact
524 of recent interventions on parasite prevalence in Tanzania.

525 The observed differences between this and recent studies, which were
526 conducted in Tanzania and showed population structure among parasites from
527 different parts of the country[68,69], could be due to the markers used, SNPs
528 and WGS data compared to microsatellites used in the current study. Validation
529 of microsatellite markers for surveillance is important because they have been
530 the gold standard tool for malaria parasite population genetics for many years.
531 Furthermore, they are cheaper and easier to access for resource-limited
532 laboratories. Ongoing and future studies will test different markers to increase
533 the resolution and robustness of capturing different population genetics metrics
534 that will be useful in assessing the impact of interventions and progress toward
535 malaria elimination in Tanzania. Additionally, optimization of markers for
536 molecular genotyping of samples collected in TES needs to be pursued as
537 recently recommended [56].

538

539 In contrast to the above findings, there was significant multilocus linkage
540 disequilibrium (LD) within populations, suggesting some level of inbreeding of
541 related parasites and repeated haplotypes, suggesting the occurrence of some
542 clonal transmission (monoclonal infections transmitted by the mosquito vector
543 in which parasite sexual recombination occurred between genetically identical
544 clones, albeit within the limitations of the markers used). An additional
545 explanation for this finding could be the presence of subpopulations within
546 populations (Wahlund effect) [70], as the samples for this study were obtained
547 from clinical sites where patients usually come from different geographic areas
548 to seek medical care. Other studies in different malaria endemic countries found
549 similar results, significant LD despite high genetic diversity and a high
550 proportion of polyclonal infection in *P. falciparum* [71,72] and *P. vivax* [73,74].
551 Detection of significant LD has important implications that could facilitate
552 inbreeding and dispersal of multilocus drug resistance haplotypes or other
553 virulent strains. As transmission decreases in Tanzania due to intensive control
554 activities, as shown elsewhere [63], the presence of LD combined with a lack
555 of geographic population structure is highly likely to facilitate such events and
556 could be a future challenge in achieving malaria elimination.

557 There was high diversity in each of the microsatellite markers, indicating that
558 few highly polymorphic markers (C2M34 and PolyA) can be used to track the

559 MOI of *P. falciparum* in Tanzania. However, the genotyped markers may have
560 limited the resolution of the population structure. The microsatellite panel used
561 had few markers (only six, with less than one per chromosome), many were
562 highly polymorphic (many alleles) and they are prone to technical artefacts [75].
563 In addition, the sample size per population was relatively limited, with
564 approximately 20 samples successfully genotyped per site. Therefore, some
565 subtle differences between populations may not be detected. For example, in
566 Kibaha, the same haplotype was found in two samples, while in all other
567 populations, all haplotypes were unique. If more samples had been genotyped,
568 additional repeated haplotypes may be found, and diversity measures altered
569 somewhat. Further analysis of large numbers of samples ($n > 50$) from additional
570 sites (again with varying transmission intensity) and utilizing larger numbers of
571 highly polymorphic microsatellite markers [31,76,77] and/or comparing them
572 with SNP barcodes [78], amplicons [79–82] and WGS [83] will be needed in an
573 effort to optimize these markers. This should also be part of the ongoing
574 initiatives to establish a molecular surveillance platform to support policy and
575 decision-making by the Tanzanian NMCP in their strategy to eliminate malaria
576 by 2030. Nevertheless, the data generated provide findings of useful markers
577 for TES and parasite populations in Tanzania, showing that there are potentially
578 large, diverse and highly intermixing parasites despite strong reductions in
579 infection prevalence and disease burden. The findings also provide useful
580 baseline information for future monitoring of parasite populations in response
581 to ongoing malaria interventions.

582 **Conclusion**

583 Microsatellite genotyping revealed high polyclonality and genetic diversity but
584 without any significant population structure. Poly- α , C2M34, C3M69 and TA1
585 were the top polymorphic markers and could be adopted for use in TES in
586 Tanzania. Failure to reveal any significant population structure among parasite
587 populations could be due to high transmission or inherent limitations of small
588 numbers of microsatellite markers and sample size. More studies covering sites
589 with varying transmission intensity, more samples and using other genotyping
590 markers will be needed for establishing an effective molecular surveillance
591 system to support implementation of TES and area-specific interventions in
592 Tanzania and monitoring the impacts of the interventions.

593 **Abbreviations**

594	ACT	Artemisinin-based combination therapy
595	AL	Artemether-lumefantrine
596	CDC	Centers for Disease Control and Prevention
597	DBS	Dried Blood Spot
598	DNA	Deoxyribonucleic acid
599	MRCC	Medical Research Coordinating Committee
600	PARMA	US PMI-supported Antimalarial Resistance Monitoring in Africa
601		Network
602	PMI	US President's Malaria Initiative
603	NIMR	National Institute for Medical Research
604	NMCP	National Malaria Control Programme
605	PCR	Polymerase Chain Reaction
606	SNP	Single nucleotide polymorphism
607	TES	Therapeutic efficacy study
608	USA	United States of America
609	WHO	World Health Organization

610

611 **Declarations**

612 **Ethical approval and consent to participate**

613 This study was approved by the MRCC of NIMR, and permission to conduct the
614 study at the four sites was obtained from the district and regional medical
615 authorities of the respective districts. Parents/guardians of all study participants
616 signed an informed consent before enrollment and provided permission to use
617 the samples for studying diversity among malaria parasites.

618 **Availability of data**

619 The microsatellite data set used for this study is available and has been
620 submitted with this paper as supplemental table 1. Additional prevalence data
621 can be obtained from the NMCP upon making an official request.

622

623 **Competing interests**

624 The authors declare that they have no competing interests.

625

626 **Funding**

627 This study was funded by USAID under the US President's Malaria Initiative
628 (PMI) through MalariaCare (PATH). Laboratory analysis at CDC was supported
629 by USAID/PMI through PARMA. The training fellowship to DSI in Australia was
630 facilitated by BIO Ventures for Global Health (BVGH) through the WIPO
631 Re:Search Fellowship Program with financial support from the Australian
632 Government through Funds-in-Trust to the World Intellectual Property
633 Organization (WIPO). DSI was also partly supported by the DELTAS Africa
634 Initiative [grant 107740/Z/15/Z]. The DELTAS Africa Initiative is an independent
635 funding scheme of the African Academy of Sciences (AAS)'s Alliance for
636 Accelerating Excellence in Science in Africa (AESAs) and supported by the New
637 Partnership for Africa's Development Planning and Coordinating Agency
638 (NEPAD Agency) with funding from the Wellcome Trust [grant 107740/Z/15/Z]
639 and the UK government. The views expressed in this publication are those of
640 the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome
641 Trust or the UK government.

642

643 **Authors' contributions**

644 DSI and RAM conceived of the idea and performed genotyping of the samples
645 at CDC. DSI, AF and AB performed the analysis of data, interpretation of results
646 and wrote the manuscript, with additional support from CIM, MW, BN, AMK,
647 MKM, EK, RAK, FM, RM, SM, RN, AM and JB, who also designed the main
648 study and took part in field data collection. DSI and CIM supervised data
649 collection and overall implementation of the field work. TM provided technical
650 and logistic support and was involved in project management at PATH. All the
651 authors have read and approved the final version of the manuscript.

652

653 **Disclaimer**

654 Ritha Njau and Marian Warsame are retired staff of the World Health
655 Organization. They alone are responsible for the views expressed in this
656 publication, which do not necessarily represent the decisions, policy or views
657 of the World Health Organization. Furthermore, the findings and conclusions in
658 this paper are those of the authors and do not necessarily represent the official
659 position of the US Centers for Disease Control and Prevention.

660

661 **Acknowledgments**

662 The authors wish to thank parents/guardians of children for taking part in the
663 study. They are grateful to the health facilities' staff, stakeholders, TES partners
664 and local health authorities for their support. Molecular analysis was undertaken
665 at the CDC with the support of the US President's Malaria Initiative-supported
666 Antimalarial Resistance Monitoring in Africa (PARMA) Network. Technical and
667 logistic support was provided by the CDC, USAID/PARMA team (Drs.

668 Udhayakumar Venkatachalam, Eric Halsey, Meera Venkatesan, Naomi Lucchi,
669 Eldin Talundzic and Lynn Paxton), PMI - Tanzania (Chonge Kitojo, Gorge Greer
670 and Erik Reaves) and NIMR staff are highly appreciated. Test drugs and filter
671 papers were provided by the WHO through its Global Malaria Programme.
672 Thanks to PATH teams (Seattle, WA and Washington DC, USA) for financial
673 and logistics support. This study was sponsored by NIMR as the host institution
674 of TES coordination on behalf of the TES Taskforce. Special appreciation to
675 Catherine Bakaria and Salehe Mandai for helping to finetune the final version of
676 the manuscript. Permission to publish this paper will be sought and granted by
677 the Director General of NIMR.

678

679 **Consent for publication**

680 Not applicable.

681 References

- 682 1. World Health Organization. World malaria report 2022 [Internet]. World
683 Health Organization; 2022. Available from:
684 <https://play.google.com/store/books/details?id=ST-hEAAAQBAJ>
- 685 2. World Health Organization. Guidelines for the Treatment of Malaria [Internet].
686 World Health Organization; 2006. Available from:
687 https://play.google.com/store/books/details?id=Am83eI7_poUC
- 688 3. National guidelines for malaria diagnosis and treatment, 2006 [Internet]. [Dar
689 es Salaam]: National Malaria Control Programme; 2006. Available from:
690 <http://www.loc.gov/catdir/toc/fy0805/2006316093.html>
- 691 4. World Health Organization. Report on antimalarial drug efficacy, resistance
692 and response: 10 years of surveillance (2010-2019) [Internet]. World Health
693 Organization; 2020. Available from:
694 <https://play.google.com/store/books/details?id=oMFqEAAAQBAJ>
- 695 5. Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS.
696 Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of
697 uncomplicated falciparum malaria in North-Eastern Tanzania. *Malar J*
698 [Internet]. 2014;13:376. Available from: <http://dx.doi.org/10.1186/1475-2875-13-376>
- 700 6. Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of
701 artemisinin-based anti-malarials for treatment of uncomplicated malaria: a
702 review of evidence of implementation of anti-malarial therapeutic efficacy trials
703 in Tanzania. *Malar J* [Internet]. 2015;14:135. Available from:
704 <http://dx.doi.org/10.1186/s12936-015-0649-8>
- 705 7. Mandara CI, Kavishe RA, Gesase S, Mghamba J, Ngadaya E, Mmbuji P, et
706 al. High efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine
707 for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma
708 Districts, Tanzania. *Malar J* [Internet]. 2018;17:261. Available from:
709 <http://dx.doi.org/10.1186/s12936-018-2409-z>
- 710 8. Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B,
711 Kamugisha E, et al. Efficacy and safety of artemisinin-based combination
712 therapy, and molecular markers for artemisinin and piperaquine resistance in
713 Mainland Tanzania. *Malar J* [Internet]. 2018;17:369. Available from:
714 <http://dx.doi.org/10.1186/s12936-018-2524-x>
- 715 9. Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B,
716 et al. Efficacy and safety of artemether-lumefantrine for the treatment of
717 uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms
718 after a decade of using artemisinin-based combination therapy in mainland
719 Tanzania. *Malar J* [Internet]. 2019;18:88. Available from:
720 <http://dx.doi.org/10.1186/s12936-019-2730-1>
- 721 10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin
722 resistance in *Plasmodium falciparum* malaria. *N Engl J Med* [Internet].

- 723 2009;361:455–67. Available from: <http://dx.doi.org/10.1056/NEJMoa0808859>
- 724 11. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al.
725 Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med*
726 [Internet]. 2008;359:2619–20. Available from:
727 <http://dx.doi.org/10.1056/NEJMc0805011>
- 728 12. Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP,
729 et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in
730 *Plasmodium falciparum* clinical isolates. *Science* [Internet]. 2015;347:428–31.
731 Available from: <http://dx.doi.org/10.1126/science.1260867>
- 732 13. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel
733 phenotypic assays for the detection of artemisinin-resistant *Plasmodium*
734 *falciparum* malaria in Cambodia: in-vitro and ex-vivo drug-response studies.
735 *Lancet Infect Dis* [Internet]. 2013;13:1043–9. Available from:
736 [http://dx.doi.org/10.1016/S1473-3099\(13\)70252-4](http://dx.doi.org/10.1016/S1473-3099(13)70252-4)
- 737 14. Arieu F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et
738 al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria.
739 *Nature* [Internet]. 2014;505:50–5. Available from:
740 <http://dx.doi.org/10.1038/nature12876>
- 741 15. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et
742 al. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater
743 Mekong subregion: a molecular epidemiology observational study. *Lancet*
744 *Infect Dis* [Internet]. 2017;17:491–7. Available from:
745 [http://dx.doi.org/10.1016/S1473-3099\(17\)30048-8](http://dx.doi.org/10.1016/S1473-3099(17)30048-8)
- 746 16. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread
747 of artemisinin-resistant *Plasmodium falciparum* in Myanmar: a cross-sectional
748 survey of the K13 molecular marker. *Lancet Infect Dis* [Internet]. 2015;15:415–
749 21. Available from: [http://dx.doi.org/10.1016/S1473-3099\(15\)70032-0](http://dx.doi.org/10.1016/S1473-3099(15)70032-0)
- 750 17. Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M,
751 Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-
752 resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda.
753 *Nat Med* [Internet]. 2020;26:1602–8. Available from:
754 <http://dx.doi.org/10.1038/s41591-020-1005-2>
- 755 18. Uwimana A, Umulisa N, Venkatesan M, Savigel SS, Zhou Z, Munyaneza T,
756 et al. Association of *Plasmodium falciparum* kelch13 R561H genotypes with
757 delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre,
758 therapeutic efficacy study. *Lancet Infect Dis* [Internet]. 2021;21:1120–8.
759 Available from: [http://dx.doi.org/10.1016/S1473-3099\(21\)00142-0](http://dx.doi.org/10.1016/S1473-3099(21)00142-0)
- 760 19. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M,
761 et al. Evidence of Artemisinin-Resistant Malaria in Africa. *N Engl J Med*
762 [Internet]. 2021;385:1163–71. Available from:
763 <http://dx.doi.org/10.1056/NEJMoa2101746>
- 764 20. Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P,

- 765 et al. Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria
766 in Eritrea. *N Engl J Med* [Internet]. 2023;389:1191–202. Available from:
767 <http://dx.doi.org/10.1056/NEJMoa2210956>
- 768 21. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C,
769 Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine
770 resistance transporter and multidrug resistance 1 genes: parasite risk factors
771 that affect treatment outcomes for P. falciparum malaria after artemether-
772 lumefantrine and artesunate-amodiaquine. *Am J Trop Med Hyg* [Internet].
773 2014;91:833–43. Available from: <http://dx.doi.org/10.4269/ajtmh.14-0031>
- 774 22. EANMAT. Monitoring antimalarial drug resistance within National Malaria
775 Control Programmes: the EANMAT experience. *Trop Med Int Health* [Internet].
776 2001;6:891–8. Available from: <http://dx.doi.org/10.1046/j.1365-3156.2001.00799.x>
- 778 23. East African Network for Monitoring Antimalarial Treatment (EANMAT). The
779 efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and
780 amodiaquine in East Africa: implications for sub-regional policy. *Trop Med Int*
781 *Health* [Internet]. 2003;8:860–7. Available from:
782 <https://onlinelibrary.wiley.com/doi/10.1046/j.1360-2276.2003.01114.x>
- 783 24. WHO. Malaria surveillance, monitoring and evaluation: a reference manual.
784 2018;
- 785 25. WHO. Methods for surveillance of antimalarial drug efficacy. 2009;
- 786 26. ZAMEP. Zanzibar guidelines for malaria diagnosis and treatment: Zanzibar
787 malaria elimination programme. Zanzibar: ZAMEP; 2014.
- 788 27. Ministry of Health. National Guidelines for Diagnosis and Treatment of
789 Malaria. Dar es Salaam, Tanzania, Ministry of Health and Social Welfare,
790 United Republic of Tanzania; 2014.
- 791 28. WHO. Tackling emerging antimalarial drug resistance in Africa [Internet].
792 Available from: <https://www.who.int/news/item/18-11-2022-tackling-emerging-antimalarial-drug-resistance-in-africa>
793
- 794 29. World Health Organization. Methods and Techniques for Clinical Trials on
795 Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations.
796 Genève, Switzerland: World Health Organization; 2007.
- 797 30. WHO. Informal consultation on methodology to distinguish reinfection from
798 recrudescence in high malaria transmission areas: report of a virtual meeting,
799 17–18 May 2021 [Internet]. World Health Organization; 2021. Available from:
800 <https://play.google.com/store/books/details?id=t3VyEAAQBAJ>
- 801 31. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L,
802 Mollinedo R, et al. Microsatellite markers reveal a spectrum of population
803 structures in the malaria parasite Plasmodium falciparum. *Mol Biol Evol*
804 [Internet]. 2000;17:1467–82. Available from:
805 <http://dx.doi.org/10.1093/oxfordjournals.molbev.a026247>

- 806 32. Tanzania ZA, Others. Tanzania: HIV/AIDS and malaria indicator survey
807 2007-08. Tanzania: HIV/AIDS and malaria indicator survey 2007-08 [Internet].
808 2008; Available from:
809 <https://www.cabdirect.org/cabdirect/abstract/20093087732>
- 810 33. Tanzania HIV/AIDS and Malaria Indicator Survey, 2011-12 [Internet].
811 Tanzania Commission for AIDS (TACAIDS); 2014. Available from:
812 <https://play.google.com/store/books/details?id=-KnsnQEACAAJ>
- 813 34. Demographic T. health survey and malaria indicator survey (TDHS-MIS)
814 2015--16. Dar es Salaam/Tanzania. 2016;
- 815 35. Ellman R, Maxwell C, Finch R, Shayo D. Malaria and anaemia at different
816 altitudes in the Muheza district of Tanzania: childhood morbidity in relation to
817 level of exposure to infection. *Ann Trop Med Parasitol* [Internet]. 1998;92:741–
818 53. Available from: <http://dx.doi.org/10.1080/00034989858989>
- 819 36. Ishengoma DS, Mmbando BP, Mandara CI, Chiduo MG, Francis F, Timiza
820 W, et al. Trends of Plasmodium falciparum prevalence in two communities of
821 Muheza district North-eastern Tanzania: correlation between parasite
822 prevalence, malaria interventions and rainfall in the context of re-emergence of
823 malaria after two decades of progressively declining transmission. *Malar J*
824 [Internet]. 2018 [cited 2023 Nov 29];17:1–10. Available from:
825 <https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-2395-1>
- 826 37. Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen
827 J, et al. Absence of seasonal variation in malaria parasitaemia in an area of
828 intense seasonal transmission. *Acta Trop* [Internet]. 1993;54:55–72. Available
829 from: [http://dx.doi.org/10.1016/0001-706x\(93\)90068-m](http://dx.doi.org/10.1016/0001-706x(93)90068-m)
- 830 38. Mandara CI, Francis F, Chiduo MG, Ngasala B, Mandike R, Mkude S, et al.
831 High cure rates and tolerability of artesunate-amodiaquine and
832 dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum
833 malaria in Kibaha and Kigoma, Tanzania. *Malar J* [Internet]. 2019;18:99.
834 Available from: <http://dx.doi.org/10.1186/s12936-019-2740-z>
- 835 39. Chacky F, Runge M, Rumisha SF, MacHafuko P, Chaki P, Massaga JJ, et
836 al. Nationwide school malaria parasitaemia survey in public primary schools,
837 the United Republic of Tanzania. *Malar J* [Internet]. 2018;17:1–16. Available
838 from: [https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-2601-1)
839 [2601-1](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-2601-1)
- 840 40. Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Félix J, et
841 al. Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine,
842 and dihydroartemisinin-piperaquine for the treatment of uncomplicated
843 Plasmodium falciparum malaria in three provinces in Angola, 2017. *Malar J*
844 [Internet]. 2018;17:144. Available from: [http://dx.doi.org/10.1186/s12936-018-](http://dx.doi.org/10.1186/s12936-018-2290-9)
845 [2290-9](http://dx.doi.org/10.1186/s12936-018-2290-9)
- 846 41. Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vredén S, et al.
847 Molecular Profile of Malaria Drug Resistance Markers of Plasmodium
848 falciparum in Suriname. *Antimicrob Agents Chemother* [Internet]. 2017;61.

- 849 Available from: <http://dx.doi.org/10.1128/AAC.02655-16>
- 850 42. Fstat JG. a computer program to calculate F-statistics. *J Hered*.
- 851 43. Haubold B, Hudson RR. LIAN 3.0: detecting linkage disequilibrium in
852 multilocus data. *Bioinformatics* [Internet]. 2000 [cited 2023 Nov 26];16:847–9.
853 Available from: [https://academic.oup.com/bioinformatics/article-
854 abstract/16/9/847/307695](https://academic.oup.com/bioinformatics/article-abstract/16/9/847/307695)
- 855 44. Evanno G, Regnaut S, Goudet J. Detecting the number of clusters of
856 individuals using the software STRUCTURE: a simulation study. *Mol Ecol*
857 [Internet]. 2005;14:2611–20. Available from: [http://dx.doi.org/10.1111/j.1365-
858 294X.2005.02553.x](http://dx.doi.org/10.1111/j.1365-294X.2005.02553.x)
- 859 45. Earl DA, vonHoldt BM. STRUCTURE HARVESTER: a website and program
860 for visualizing STRUCTURE output and implementing the Evanno method.
861 *Conserv Genet Resour* [Internet]. 2012;4:359–61. Available from:
862 <https://doi.org/10.1007/s12686-011-9548-7>
- 863 46. Jakobsson M, Rosenberg NA. CLUMPP: a cluster matching and
864 permutation program for dealing with label switching and multimodality in
865 analysis of population structure. *Bioinformatics* [Internet]. 2007;23:1801–6.
866 Available from: <http://dx.doi.org/10.1093/bioinformatics/btm233>
- 867 47. Nei M. *Molecular Evolutionary Genetics* [Internet]. Columbia University
868 Press; 1987. Available from:
869 <https://play.google.com/store/books/details?id=UhRSsLkixDgC>
- 870 48. Goudet J. hierfstat, a package for r to compute and test hierarchical *F*-
871 statistics. *Mol Ecol Notes* [Internet]. 2005;5:184–6. Available from:
872 <https://onlinelibrary.wiley.com/doi/10.1111/j.1471-8286.2004.00828.x>
- 873 49. Jombart T. adegenet: a R package for the multivariate analysis of genetic
874 markers. *Bioinformatics* [Internet]. 2008;24:1403–5. Available from:
875 <http://dx.doi.org/10.1093/bioinformatics/btn129>
- 876 50. Paradis E, Claude J, Strimmer K. APE: Analyses of Phylogenetics and
877 Evolution in R language. *Bioinformatics* [Internet]. 2004;20:289–90. Available
878 from: <http://dx.doi.org/10.1093/bioinformatics/btg412>
- 879 51. Nkhoma SC, Nair S, Cheeseman IH, Rohr-Allegrini C, Singlam S, Nosten
880 F, et al. Close kinship within multiple-genotype malaria parasite infections. *Proc*
881 *Biol Sci* [Internet]. 2012;279:2589–98. Available from:
882 <http://dx.doi.org/10.1098/rspb.2012.0113>
- 883 52. Jost L. GST and its relatives do not measure differentiation. *Mol Ecol*
884 [Internet]. 2008;17:4015–26. Available from: [https://doi.org/10.1111/j.1365-
885 294X.2008.03887.x](https://doi.org/10.1111/j.1365-294X.2008.03887.x)
- 886 53. WHO. Informal consultation on methodology to distinguish reinfection from
887 recrudescence in high malaria transmission areas: report of a virtual meeting,
888 17–18 May 2021 [Internet]. World Health Organization; 2021. Available from:

- 889 <https://play.google.com/store/books/details?id=t3VyEAAAQBAJ>
- 890 54. Jones S, Plucinski M, Kay K, Hodel EM, Hastings IM. A Computer Modelling
891 Approach To Evaluate the Accuracy of Microsatellite Markers for Classification
892 of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy.
893 Antimicrob Agents Chemother [Internet]. 2020;64. Available from:
894 <http://dx.doi.org/10.1128/AAC.01517-19>
- 895 55. Plucinski MM, Barratt JLN. Nonparametric Binary Classification to
896 Distinguish Closely Related versus Unrelated Plasmodium falciparum
897 Parasites. Am J Trop Med Hyg [Internet]. 2021;104:1830–5. Available from:
898 <http://dx.doi.org/10.4269/ajtmh.21-0117>
- 899 56. Hastings IM, Felger I. WHO antimalarial trial guidelines: good science, bad
900 news? Trends Parasitol [Internet]. 2022;38:933–41. Available from:
901 <http://dx.doi.org/10.1016/j.pt.2022.08.005>
- 902 57. Nkhoma SC, Trevino SG, Gorena KM, Nair S, Khoswe S, Jett C, et al. Co-
903 transmission of Related Malaria Parasite Lineages Shapes Within-Host
904 Parasite Diversity. Cell Host Microbe [Internet]. 2020;27:93–103.e4. Available
905 from: <http://dx.doi.org/10.1016/j.chom.2019.12.001>
- 906 58. Bérubé S, Freedman B, Menya D, Kipkoech J, Abel L, Lapp Z, et al.
907 Superinfection plays an important role in the acquisition of complex
908 Plasmodium falciparum infections among female Anopheles mosquitoes
909 [Internet]. bioRxiv. 2022 [cited 2023 Nov 30]. p. 2022.12.23.521802. Available
910 from: <https://www.biorxiv.org/content/10.1101/2022.12.23.521802v1>
- 911 59. Fola AA, Harrison GLA, Hazairin MH, Barnadas C, Hetzel MW, Iga J, et al.
912 Higher Complexity of Infection and Genetic Diversity of Plasmodium vivax Than
913 Plasmodium falciparum Across All Malaria Transmission Zones of Papua New
914 Guinea. Am J Trop Med Hyg [Internet]. 2017;96:630–41. Available from:
915 <http://dx.doi.org/10.4269/ajtmh.16-0716>
- 916 60. Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, Nale J, et al. Multilocus
917 haplotypes reveal variable levels of diversity and population structure of
918 Plasmodium falciparum in Papua New Guinea, a region of intense perennial
919 transmission. Malar J [Internet]. 2010;9:336. Available from:
920 <http://dx.doi.org/10.1186/1475-2875-9-336>
- 921 61. Barry AE, Schultz L, Senn N, Nale J, Kiniboro B, Siba PM, et al. High levels
922 of genetic diversity of Plasmodium falciparum populations in Papua New
923 Guinea despite variable infection prevalence. Am J Trop Med Hyg [Internet].
924 2013;88:718–25. Available from: <http://dx.doi.org/10.4269/ajtmh.12-0056>
- 925 62. Noviyanti R, Coutrier F, Utami RAS, Trimarsanto H, Tirta YK, Trianty L, et
926 al. Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and
927 P. falciparum: Implications for Malaria Control and Elimination. PLoS Negl Trop
928 Dis [Internet]. 2015;9:e0003739. Available from:
929 <http://dx.doi.org/10.1371/journal.pntd.0003739>
- 930 63. Kattenberg JH, Razook Z, Keo R, Koepfli C, Jennison C, Lautu-Gumal D,

- 931 et al. Monitoring *Plasmodium falciparum* and *Plasmodium vivax* using
932 microsatellite markers indicates limited changes in population structure after
933 substantial transmission decline in Papua New Guinea. *Mol Ecol* [Internet].
934 2020;29:4525–41. Available from: <http://dx.doi.org/10.1111/mec.15654>
- 935 64. Sáenz FE, Morton LC, Okoth SA, Valenzuela G, Vera-Arias CA, Vélez-
936 Álvarez E, et al. Clonal population expansion in an outbreak of *Plasmodium*
937 *falciparum* on the northwest coast of Ecuador. *Malar J* [Internet]. 2015;13 Suppl
938 1:497. Available from: <http://dx.doi.org/10.1186/s12936-015-1019-2>
- 939 65. Griffing SM, Mixson-Hayden T, Sridaran S, Alam MT, McCollum AM,
940 Cabezas C, et al. South American *Plasmodium falciparum* after the malaria
941 eradication era: clonal population expansion and survival of the fittest hybrids.
942 *PLoS One* [Internet]. 2011;6:e23486. Available from:
943 <http://dx.doi.org/10.1371/journal.pone.0023486>
- 944 66. Volkman SK, Ndiaye D, Diakite M, Koita OA, Nwakanma D, Daniels RF, et
945 al. Application of genomics to field investigations of malaria by the international
946 centers of excellence for malaria research. *Acta Trop* [Internet]. 2012;121:324–
947 32. Available from: <http://dx.doi.org/10.1016/j.actatropica.2011.12.002>
- 948 67. WHO. Informal consultation on methodology to distinguish reinfection from
949 recrudescence in high malaria transmission areas. 2021;
- 950 68. Moser KA, Madebe RA, Aydemir O, Chiduo MG, Mandara CI, Rumisha SF,
951 et al. Describing the current status of *Plasmodium falciparum* population
952 structure and drug resistance within mainland Tanzania using molecular
953 inversion probes. *Mol Ecol* [Internet]. 2021;30:100–13. Available from:
954 <http://dx.doi.org/10.1111/mec.15706>
- 955 69. Morgan AP, Brazeau NF, Ngasala B, Mhamilawa LE, Denton M, Msellem
956 M, et al. *Falciparum* malaria from coastal Tanzania and Zanzibar remains highly
957 connected despite effective control efforts on the archipelago. *Malar J* [Internet].
958 2020;19:47. Available from: <http://dx.doi.org/10.1186/s12936-020-3137-8>
- 959 70. Wahlund S. ZUSAMMENSETZUNG VON POPULATIONEN UND
960 KORRELATIONSERSCHEINUNGEN VOM STANDPUNKT DER
961 VERERBUNGSLEHRE AUS BETRACHTET. *Hereditas* [Internet]. 2010;11:65–
962 106. Available from: <http://doi.wiley.com/10.1111/j.1601-5223.1928.tb02483.x>
- 963 71. Ruybal-Pesántez S, Tiedje KE, Rorick MM, Amenga-Etego L, Ghansah A,
964 R Oduro A, et al. Lack of Geospatial Population Structure Yet Significant
965 Linkage Disequilibrium in the Reservoir of *Plasmodium falciparum* in Bongo
966 District, Ghana. *Am J Trop Med Hyg* [Internet]. 2017;97:1180–9. Available from:
967 <http://dx.doi.org/10.4269/ajtmh.17-0119>
- 968 72. Durand P, Michalakis Y, Cestier S, Oury B, Leclerc MC, Tibayrenc M, et al.
969 Significant linkage disequilibrium and high genetic diversity in a population of
970 *Plasmodium falciparum* from an area (Republic of the Congo) highly endemic
971 for malaria. *Am J Trop Med Hyg* [Internet]. 2003 [cited 2023 Nov 26];68:345–9.
972 Available from:
973 <https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=d87c03de1>

- 974 746b4fdd6e8cfb4f59c316e0cfe1651
- 975 73. Fola AA, Nate E, Abby Harrison GL, Barnadas C, Hetzel MW, Iga J, et al.
976 Nationwide genetic surveillance of Plasmodium vivax in Papua New Guinea
977 reveals heterogeneous transmission dynamics and routes of migration
978 amongst subdivided populations. *Infect Genet Evol* [Internet]. 2018;58:83–95.
979 Available from: <http://dx.doi.org/10.1016/j.meegid.2017.11.028>
- 980 74. Waltmann A, Koepfli C, Tessier N, Karl S, Fola A, Darcy AW, et al.
981 Increasingly inbred and fragmented populations of Plasmodium vivax
982 associated with the eastward decline in malaria transmission across the
983 Southwest Pacific. *PLoS Negl Trop Dis* [Internet]. 2018;12:e0006146. Available
984 from: <http://dx.doi.org/10.1371/journal.pntd.0006146>
- 985 75. Madesis P, Ganopoulos I, Tsaftaris A. Microsatellites: evolution and
986 contribution. *Methods Mol Biol* [Internet]. 2013;1006:1–13. Available from:
987 http://dx.doi.org/10.1007/978-1-62703-389-3_1
- 988 76. Aydemir O, Janko M, Hathaway NJ, Verity R, Mwandagalirwa MK, Tshetu
989 AK, et al. Drug-Resistance and Population Structure of Plasmodium falciparum
990 Across the Democratic Republic of Congo Using High-Throughput Molecular
991 Inversion Probes. *J Infect Dis* [Internet]. 2018;218:946–55. Available from:
992 <http://dx.doi.org/10.1093/infdis/jiy223>
- 993 77. Tessema SK, Raman J, Duffy CW, Ishengoma DS, Amambua-Ngwa A,
994 Greenhouse B. Applying next-generation sequencing to track falciparum
995 malaria in sub-Saharan Africa. *Malar J* [Internet]. 2019;18:268. Available from:
996 <http://dx.doi.org/10.1186/s12936-019-2880-1>
- 997 78. Daniels R, Volkman SK, Milner DA, Mahesh N, Neafsey DE, Park DJ, et al.
998 A general SNP-based molecular barcode for Plasmodium falciparum
999 identification and tracking. *Malar J* [Internet]. 2008;7:223. Available from:
1000 <http://dx.doi.org/10.1186/1475-2875-7-223>
- 1001 79. Miller RH, Hathaway NJ, Kharabora O, Mwandagalirwa K, Tshetu A,
1002 Meshnick SR, et al. A deep sequencing approach to estimate Plasmodium
1003 falciparum complexity of infection (COI) and explore apical membrane antigen
1004 1 diversity. *Malar J* [Internet]. 2017;16:490. Available from:
1005 <http://dx.doi.org/10.1186/s12936-017-2137-9>
- 1006 80. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, et
1007 al. Development of amplicon deep sequencing markers and data analysis
1008 pipeline for genotyping multi-clonal malaria infections. *BMC Genomics*
1009 [Internet]. 2017;18:864. Available from: <http://dx.doi.org/10.1186/s12864-017-4260-y>
- 1010
- 1011 81. Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela
1012 I, et al. Longitudinal tracking and quantification of individual Plasmodium
1013 falciparum clones in complex infections. *Sci Rep* [Internet]. 2019;9:3333.
1014 Available from: <http://dx.doi.org/10.1038/s41598-019-39656-7>
- 1015 82. Juliano JJ, Porter K, Mwapasa V, Sem R, Rogers WO, Arieu F, et al.

- 1016 Exposing malaria in-host diversity and estimating population diversity by
1017 capture-recapture using massively parallel pyrosequencing. Proc Natl Acad Sci
1018 U S A [Internet]. 2010;107:20138–43. Available from:
1019 <http://dx.doi.org/10.1073/pnas.1007068107>
- 1020 83. Auburn S, Benavente ED, Miotto O, Pearson RD, Amato R, Grigg MJ, et al.
1021 Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population
1022 reveals selective pressures and changing transmission dynamics. Nat
1023 Commun [Internet]. 2018;9:2585. Available from:
1024 <http://dx.doi.org/10.1038/s41467-018-04965-4>.